Objectives. The incidence of thromboembolism in patients with SLE is higher than that in the general population. HCQ, widely used to treat lupus, may have vascular protective effects. The aim of this study was to determine whether long-term HCQ exposure is associated with decreased thromboembolism risk in SLE.
Introduction
SLE is an autoimmune disease that often involves multiple organs and many different manifestations. Among them, thromboembolic disease is a major cause of morbidity and mortality, and is the most common cause of death in the late stages of SLE [1] . Although the pathogenesis of the disease is still uncertain, thromboembolism may affect both the venous and arterial circulatory systems [2] . In a large observational cohort, the estimated 20-year risk was 10% for venous thrombotic events (TEs), 26% for arterial TEs and 33% for any TEs [3] . Although there is increasing awareness of the disease, the frequency of hospitalization for associated events has not decreased [4] . In Taiwan, patients with SLE are also at an increased risk of vascular events, including acute coronary syndrome (ACS), ischaemic stroke, pulmonary embolism (PE), deep vein thrombosis (DVT) and peripheral arterial disease (PAD) [58] .
Universal preventative medications for thromboembolism are aspirin, warfarin, statins and so on. Conflicting opinions exist with respect to whether immune-associated treatment methods have a major role in decreasing the development of thromboembolism [9] . Among these medications, HCQ is the mostly widely prescribed to control SLE disease activity. Regarding the protective effect of HCQ against thromboembolism, inconsistent opinions have been expressed in the literature. In a prospective cohort, the LUpus in MInorities NAture vs nurture Study Group explored the use of HCQ and determined that it did not confer a significant protective effect from vascular events in a multivariate model [10] . However, later cohort studies indicated that HCQ was protective against the development of thromboembolic disease [11, 12] , although not in a time-dependent manner. One research group suggested that further studies were needed to determine whether HCQ could persistently decrease the incidence of thromboembolic events in patients with SLE [11] .
With the above in mind, we designed a prospective cohort study with strict selection and matching to determine whether long-term HCQ affects the overall risk of thromboembolism in patients with SLE in Taiwan.
Methods

Study design
This is a prospective study based on data from a healthcare database. We included patients who were diagnosed as having new-onset SLE between 1 January 2001 and 31 December 2013 and whose data were available in the Taiwan National Health Insurance Research Database (NHIRD). Our database covered the claim data between 1997 and 2013. Therefore, each subject had at least 4 years of medical records (i.e. 19972000) to identify their old SLE diagnosis or to exclude composite vascular events before the index date. We subdivided the study participants into the HCQ and control groups in the first year. The major outcomes were composite vascular events, which included ACS, acute ischaemic stroke, PE, DVT and PAD, occurring from 1 year after SLE diagnosis. We excluded patients from the cohort if they had outcomes within the first year.
The numbers and letters from the English alphabet have been used by NHIRD as identifying codes to replace the name and ID of patients to protect their privacy. Because the researcher cannot identify individual data from NHIRD, informed patient consent was not necessary for the study. The study was approved by the Chang Gung Medical Foundation Institutional Review Board, No. 201600892B1.
Brief background of Taiwan's National Health Insurance and NHIRD Taiwan's National Health Insurance (NHI) system is a single-payer national health insurance scheme that currently covers >96% of Taiwan's population. It is a form of social insurance [13, 14] . Every Taiwanese person who is registered in the census for >6 months is required to join the NHI programme. When individuals are included in the NHI programme, they can attend outpatient visits, the emergency room and admission services. Healthcare services include diagnosis by a physician, blood tests such as biochemistry, complete blood count, imaging studies such as chest X-ray and CT, medication and surgery [15] .
Eligibility for inclusion and exclusion
Between 1 January 2001 and 31 December 2013, a total of 41 626 patients with SLE [international Classification of Disease (ICD)-9: 710.0] in the NHIRD were initially screened. SLE diagnoses were verified according to the catastrophic illness certification (CIC) in line with the regulations of the NHI programme [16, 17] . In summary, the specialist submitted the CIC application, which was reviewed anonymously by another senior and experienced rheumatologist assigned by the NHI administration. The reviewing process was based on the 1997 ACR criteria, in which four or more of the manifestations had to be present [18] .
We only included the first SLE diagnosis of each patient, so patients with SLE diagnosed date before 1 January 2001 were excluded. We excluded patients whose diagnosis did not pass the CIC procedure and patients with ACS, any stroke, PE, DVT or PAD before the diagnosis of SLE. After applying these exclusion criteria, a total of 14 216 new-onset SLE patients who passed the CIC procedure outlined above were identified. Furthermore, we excluded any patient who was followed up for <1 year, because we needed 1 year of data to identify whether the patients' characteristics matched those of the HCQ or control group. Any patients who developed vascular events in the first year were excluded due to insufficient time to assess HCQ exposure (Fig. 1) . We did not increase the additional follow-up time for determining the occurrence of the outcome variable (i.e. at least 3 years) mainly because this would exclude many patients between 2011 and 2013. Therefore, the event rate may be under-estimated for those with a relatively short follow-up (i.e. <3 years). However, the mean follow-up period (7.4 years) would be enough to follow up major vascular events.
Exposure to HCQ
Medication possession ratio (MPR) was defined as the ratio of doses available to a patient to a fixed period of time [19] . The first-year MPR was defined as the MPR during the first 365 follow-up days. We also excluded 3986 patients who were prescribed HCQ but had a firstyear MPR <80% (<292 days). Finally, 8397 patients were eligible for analysis and were further divided into the HCQ www.rheumatology.oxfordjournals.org and control groups. We defined the HCQ group (n = 6011) by good adherence to HCQ treatment with a first year MPR 5 80% (292 days at least in the first year) and the control group (n = 2386) by no use of HCQ (0 days of 365 days). After propensity score matching, each study group contained 1946 patients (Fig. 1) . In the study cohort, the daily HCQ dose was between 200 and 400 mg.
The null hypothesis in this study was that the effect of HCQ on cardiovascular disease was neutral; thus, a priori sample size determination based on the relevant existing evidence was required. A previous study assessed the effect of HCQ on cardiovascular disease in patients with RA [20] . The event rates were 0.52% (3/547) and 13.77% (99/719) in the HCQ and non-HCQ groups, respectively. For the effect size after reducing the event rate of the HCQ by 13.25% (13.77, 0.52), a minimum sample size of 197 in each study group was required to achieve a power level of 95% and an alpha level of 5%. This power calculation ensured that there was sufficient power in our pre-specified subgroup analysis of age group, gender, hypertension (HTN), diabetes mellitus (DM), dyslipidaemia, chronic kidney disease (CKD), coronary artery disease (CAD), aspirin use, statin use, and NSAID use.
Covariate measurements and propensity score matching
The SLE diagnostic date were assigned as the index date. For comorbidities such as HTN, DM, dyslipidaemia, gout, CKD, CAD and malignancy, there had to be two records of an outpatient diagnosis or one diagnosis with admission within 1 year before the index date using ICD-9-CM diagnosis codes (supplementary Table S1 , available at Rheumatology Online). Overlapping immune diseases, including SS and RA, were defined as the presence of the relevant ICD numbers in at least two records of an outpatient principal diagnosis or one diagnosis with admission during the first year after the index date. SS and RA are the two most common autoimmune rheumatic diseases in Taiwan [21, 22] . Medications, including aspirin, statins, warfarin, NSAIDs, systemic glucocorticoids, AZA, CYC and MTX, had to be prescribed for at least 90 days or at least twice in outpatient departments during the first FIG. 1 Flowchart of the study design year after the index date. The number of admissions due to SLE was calculated during the first year after the index date.
To minimize selection bias due to non-randomized allocation during the first year of follow-up, we performed propensity score matching to balance the baseline characteristics, comorbidities and SLE severity between the study groups. We used nearest-neighbour matching using pre-specified calipers (= 0.2 of the standard deviation of the logit of the propensity score) without replacement with a 1:1 matching ratio [23] . We matched each patient in the HCQ group with a patient in the control group using propensity scores, which were derived from the characteristics (age and gender), comorbidities, medications, overlapping immune diseases, number of admissions due to SLE and year of index date.
Outcomes
The mechanisms of venous thrombosis and atherosclerosis are different, but there might be a link between them [24, 25] . With this in mind, we combined major vascular events into a composite vascular outcome according to a previous study [26] . The primary end point was hospitalization or an emergency visit due to the composite vascular outcome, including ACS, ischaemic stroke, PE, DVT or PAD. The secondary endpoints were all separate vascular events. The follow-up period was based on the index date of SLE diagnosis to the date of a vascular event, death or 31 December 2013.
Statistical analysis
We compared the patients' characteristics between the HCQ and control groups before propensity score matching using an independent-sample t test for continuous variables or the chi-square test for categorical variables. However, because of the paired nature after matching, data between the HCQ and control groups were compared using the paired-sample t test for continuous variables or the McNemar test for categorical variables. The incidence of outcomes of interest (both primary and secondary outcomes) was reported as the event rate (proportion of events) and incidence density (number of events per 1000 person-years). We compared the risk of time-to-event outcomes using a Cox proportional hazard model without additional adjustment because propensity score matching had already been performed. The proportional hazard assumption was checked by analysing Schoenfeld partial residuals. Data analysis and propensity score matching were conducted using SAS software version 9.4 (SAS Institute, Cary, NC, USA). Table 1 presents patient characteristics before and after propensity score matching. Before matching (left panel in Table 1 ), patients in the HCQ group had a lower prevalence of comorbidities (e.g. HTN, dyslipidaemia and CKD), were more likely to be prescribed some medications (e.g. aspirin, NSAIDs, corticosteroids, AZA and MTX) and less likely to be prescribed others (e.g. except statin and CYC), and had a higher incidence of overlapping immune diseases (e.g. SS and RA) during the first year of follow-up. We selected some variables (e.g. immunosuppressant use, number of admissions due to SLE and associated immune diseases) as proxies for SLE severity. The HCQ group had a lower annual number of hospitalizations due to SLE during the first year of follow-up. After matching, the distribution of patient characteristics between the study groups was homogeneous and comparable (right panel in Table 1 ).
Results
Study patients
Primary composite outcome and secondary outcomes During a mean (S.D.) 7.4 (3.5) years of follow-up, the event rate of the composite vascular outcome was 139% (7.1%) in the HCQ group and 149% (7.7%) in the control group (Table 2) . Testing of Schoenfeld partial residuals for the primary composite outcome revealed an insignificant correlation (number of events = 288, r = 0.118), which indicated that the assumption of proportional hazard was not violated. We also noted that the risk of vascular events was comparable between the two groups [hazard ratio (HR) = 0.91; 95% CI: 0.72, 1.15]. The cumulative incidence of vascular events during follow-up is depicted in Fig. 2 . With respect to the components of the composite vascular outcome (secondary outcomes), no group differences were observed in terms of the incidence of ACA, ischaemic stroke, PE, DVT and PAD (Table 2 ).
Subgroup analysis of the primary composite outcome and secondary outcomes Further subgroup analysis of the composite vascular outcome was performed according to the following predefined subgroups: age group, gender, HTN, DM, dyslipidaemia, CKD, CAD, aspirin use, statin use and NSAID use. The observed neutral effect of HCQ was similar and comparable among all these subgroups (Fig. 3) . In subgroup analysis of the secondary endpoints (supplementary Tables S2S5, available at Rheumatology Online), SLE patients without HTN could get a significant protective effect of HCQ from DVT (HR = 0.36, 95% CI: 0.17, 0.74) (supplementary Table S4 , available at Rheumatology Online).
Subgroup analysis of different HCQ doses
To determine whether different doses of HCQ resulted in different outcomes, we divided the HCQ group into two subgroups (<300 mg vs 5300 mg) according to average daily HCQ dose. Further subgroup analyses of the composite vascular outcome and secondary outcomes were performed according to these HCQ dose subgroups. There were no significant differences between the highand low-dose groups (Table 3) .
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Discussion
This large scale SLE cohort study demonstrated that patients treated with HCQ had a similar incidence of vascular events to those in the control group. The protective effect of HCQ has been reported in previous studies, but impact of the duration of exposure has not been investigated [11, 12] . Thus, the differences in clinical vascular outcomes between long-term users and non-users of HCQ remain unclear. The results of the present study show that HCQ has a neutral effect on vascular events in patients with SLE.
Although several studies have reported the efficacy of HCQ for preventing thromboembolism [11, 12, 27, 28] , overall, the data are inconsistent. Ho et al.
[10] reported no independent effect of HCQ against vascular events in a prospective cohort. Similarly, two studies by Mok et al. [29, 30] did not find a protective effect of HCQ against thrombosis. In the study of Bessant et al. [31] HCQ did not decrease the risk of cardiovascular disease (CVD) in multivariate analysis.
These inconsistencies might be the result of the fact that most studies defined exposure to HCQ as ever treated or treated prior to the vascular event. The resultant possibility of an immortal time bias would induce researchers to over-evaluate the protective effects of HCQ [32, 33] . Without considering when HCQ exposure started, unexposed time can be misclassified as exposed time. Since the outcome could not have occurred during the immortal period, an undue advantage is conferred to the HCQ-exposed group. As a result, the estimated HR of exposure gives the impression that HCQ is much more effective in preventing vascular events than it actually is. Only the study by Ruiz-Irastorza et al. [28] analysed the relationship between HCQ and thrombosis in a timedependent manner, but the cohort included only 232 patients with SLE. In fact, non-adherence to HCQ was common [34] , so ever or never use is not an appropriate variable to survey the efficacy of HCQ. In order to determine the long-term effect of HCQ and to avoid immortal time bias, we decided to compare patients who had never used HCQ with those whose MPR was 580% in the first year.
We were also concerned about the vascular protection effect of HCQ reported in a previous study [12] because it is almost impossible to avoid confounding by indications Anyone with acute coronary syndrome, ischaemic stroke, pulmonary embolism, deep vein thrombosis or peripheral artery disease. One of the hypotheses explaining how HCQ might protect against CVD is based on the possible benefits of HCQ in reducing low-density lipoprotein cholesterol levels [36] . However, several controversies surround this idea in the literature. For example, HCQ had no significant effect on lipids and apolipoproteins in Chinese patients with SLE [37] . After adjustment for statin and steroid intake, HCQ use had no impact on cholesterol profiles in the survey of Rossoni et al. [38] . The clinical effect of HCQ on the lipid profiles of SLE patients could not be confirmed based on the currently available evidence, which is rather weak [39] .
Racial differences may modulate the effect of HCQ [40] and lead to different presentations of SLE. For example, HCQ might induce specific pericentral pattern retinopathies among Asian patients exclusively [41] . There are also inter-ethnic differences in the damage pattern [42] and incidence of thromboembolism [30] in patients with SLE, which cannot be fully explained by the clinical factors studied. The fact that Asian individuals with SLE are at risk of more severe and more destructive disease [43] might also explain the insignificant thromboembolic protective effect of HCQ in such patients.
Chronic inflammation, aPL and exposure to steroid therapy are all likely to have an impact on increasing the risk of CVD in patients with SLE [5, 6] . It seems rational to classify SLE patients as a high-cardiovascular-risk group, and the majority are treated with aspirin prophylaxis [44] and dyslipidaemia correction. In contrast to the unclear effect of HCQ, statins are the most recommended drugs for achieving lipid profile treatment targets [45] . The relative safety of HCQ may position it as an adjunct in a large proportion of SLE patients in preventing vascular event, but it probably cannot play a leading role in treatment.
Our study used a highly selective process to confirm that the composite vascular events were valid. Only newly onset events were considered as the end point because the repeated events were difficult to confirm in the coding system of NHIRD. Besides, we are uncertain whether different events could affect each other. We needed 1 year of data to subdivide the participants into the HCQ and control groups, so we excluded patients with vascular events in the first year instead of ignoring the events. We excluded 264 patients with vascular events, which is a relatively small number in comparison with the 8397 eligible patients for analysis. Therefore, the exclusion should have only a minor effect on the results of the study.
We have designated all separate vascular events as secondary endpoints. No significant decrease in risk was found in the HCQ group. We found that HCQ might have a trend of protective effect (P = 0.069) from DVT (Table 2) . Further subgroup analysis for these relatively Table S4 , available at Rheumatology Online). High blood pressure may increase the risk of DVT [46] . Therefore, in non-HTN patients, DVT is more likely to be associated by immune-related problems, such as aPL, which could be controlled with the immunomodulation of HCQ [47] . However, owing to the protective effect found in a subgroup analysis of the secondary end point, future studies are needed to prove the hypothesis. A subgroup analysis of different average daily HCQ doses showed a comparable observed protective effect on neutral vascular events. HCQ has no dose-dependent effect on vascular events in SLE patients.
The present study has some limitations. First, there exist some essential defects in the database. For example, the prevalence of APS was unknown because there is no specific diagnostic code for APS in the ICD-9-CM diagnosis codes. APS is an autoimmune disorder that can manifest as vascular events and often appears in patients with SLE. In order to conquer the problem, we identified prescriptions that might be used to treat APS, such as aspirin and warfarin, and matched them as precisely as possible. Disease activity, information about which was not available in the database, may affect outcomes. Therefore, in addition to the general variable age, gender, comorbidities and overlapping immune diseases, we matched the variables that may be associated with activity, including immunosuppressants and the number of admissions due to SLE according to the method used in a previous study [17] . We made an extensive effort to minimize the impact of this limitation through the use of propensity score matching.
Second, almost all participants were Taiwanese, so the external validity of the results is doubtful. As described above, more severe and destructive activity of SLE in Asians might limit the effect of HCQ. Further studies in other ethnic groups will be necessary to further validate the results of the present study; however, the result of this large-scale study clarifies the effect of long-term HCQ in the prevention of vascular events in Asian patients with SLE.
Finally, this was not a randomized controlled trial; we used a prospective design. We did not include the data related to HCQ use after the first year of the follow-up. Currently, a prospective randomized controlled trial concerning the protective effect of HCQ against recurrent cardiovascular events in myocardial infarction patients is on-going [48] , but the study does not include patients with SLE. In fact, HCQ is used universally in patients with SLE for its other benefits and good safety profile. It seems unethical to design a prospective, placebo-controlled www.rheumatology.oxfordjournals.org randomized trial with a group of SLE patients from whom HCQ is deliberately withheld. Thus, the present study, with its use of propensity score analysis adjusted for a number of associated variables, offers the best evidence currently available.
In conclusion, long-term HCQ therapy, regardless of dose, seemed ineffective for reducing the risk of vascular events in patients with SLE. The effect of HCQ therapy on thromboembolism in patients with SLE may not be overestimated.
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